Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofol Sedation for Liver Cancer Ablation
NCT06178926Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Randomised, double-blind trial of ciprofol (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Sedation efficacy (MOAA/S score). Started Aug 2023; status: recruiting.
02
Drugs
ciprofol
Beyond the preview
Go deeper on NCT06178926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06178926.